| 050A760 |
| 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxam |
| 15160-EP2272827A1 |
| 15160-EP2275420A1 |
| 15160-EP2280012A2 |
| 15160-EP2281815A1 |
| 15160-EP2289892A1 |
| 15160-EP2292615A1 |
| 15160-EP2295055A2 |
| 15160-EP2295416A2 |
| 15160-EP2295426A1 |
| 15160-EP2295427A1 |
| 15160-EP2298748A2 |
| 15160-EP2298764A1 |
| 15160-EP2298765A1 |
| 15160-EP2301928A1 |
| 15160-EP2301933A1 |
| 15160-EP2305640A2 |
| 15160-EP2305642A2 |
| 15160-EP2305671A1 |
| 15160-EP2308833A2 |
| 15160-EP2311453A1 |
| 15160-EP2311808A1 |
| 15160-EP2311827A1 |
| 15160-EP2311829A1 |
| 15160-EP2311842A2 |
| 15160-EP2316832A1 |
| 15160-EP2316833A1 |
| 1CC1JFE158 |
| 2-Amino- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxylic acid bis- [(5,12-diisopropyl- 9,13,16-trimethyl- 4,7,11,14,17-pentaoxo- hexadecahydro- 10-oxa- 3a,6,13,16-tetraaza- cyclopentacyclohexadecen- 8-yl)- amide] |
| 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamid |
| 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamid |
| 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide |
| 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo- |
| 50-76-0 |
| AB00514445-05 |
| AC1L9W52 |
| ACT [antibiotic] |
| Actactinomycin A IV |
| ActD |
| Actinomycin |
| Actinomycin 7 |
| Actinomycin C1 |
| actinomycin D |
| Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp. |
| Actinomycin D, from Streptomyces sp., >=95% (HPLC) |
| Actinomycin D, from Streptomyces sp., ~98% (HPLC) |
| Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95% |
| Actinomycin IV |
| AI3-26374 |
| AKOS030228553 |
| BDBM43866 |
| BDBM50089528 |
| BRD-K70578146-001-01-8 |
| CAS-50-76-0 |
| CCG-101134 |
| CHEBI:27666 |
| CHEMBL1554 |
| CHEMBL3792960 |
| cid_457193 |
| Cosmegen Lyovac |
| CPD000469227 |
| CTK8F7580 |
| Dactinomicina |
| DACTINOMYCIN |
| Dactinomycin [USAN:USP:INN:BAN] |
| Dactinomycin, United States Pharmacopeia (USP) Reference Standard |
| Dactinomycine |
| Dactinomycinum |
| DB00970 |
| Dilactone actinomycindioic D acid |
| DSSTox_CID_31 |
| DSSTox_GSID_20031 |
| DSSTox_RID_75330 |
| DTXSID9020031 |
| DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA |
| EINECS 200-063-6 |
| FT-0080366 |
| Glycopeptide, 4a |
| GNF-Pf-2290 |
| HMS2052O17 |
| Lyovac-Cosmegen |
| Meractinomycin |
| MFCD00005033 |
| MLS001424196 |
| MolPort-003-925-177 |
| NC00384 |
| NCGC00090796-01 |
| NCGC00161622-01 |
| NCGC00161622-02 |
| NCGC00260031-01 |
| NCGC00271789-02 |
| NCI-C04682 |
| NSC 3053 |
| NSC3053 |
| PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA |
| RJURFGZVJUQBHK-IIXSONLDSA-N |
| SAM001246846 |
| SCHEMBL3844 |
| SMR000469227 |
| Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-me |
| Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo |
| Tox21_111997 |
| Tox21_111997_1 |
| Tox21_202482 |
| UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N |
| UNII-1CC1JFE158 |
| UPCMLD-DP055 |
| UPCMLD-DP055:001 |
| UPCMLD-DP055:002 |
